Psoriatic arthritis trials in Italy

In Italy 16 Also abroad 116

16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
Where
Florence, Reggio Emilia
People
339 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00
Phase 3Taking people
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Where
Brescia, Chieti, Genova, Milan, Naples, Palermo, Trieste
Age
1 year to 18 years
People
190 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT03773965
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Bergamo, Bologna, Rome, San Giovanni Rotondo, Trieste
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
No phaseTaking people
A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting
Where
Bari, Brescia, Iesi, Milan, Naples, Palermo, Pavia, Perugia, Pisa, Potenza, Reggio Emilia, Roma, Siena, Torino, Varese, Verona
Age
18 years and over
People
200
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07220824
No phaseTaking people
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Where
Rome
Age
Up to 21 years
People
20,000 worldwide
Run by
Duke University
See details and how to joinNCT02418442
Phase 3Taking people
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Where
Chieti, Genoa, Milan, Rome
Age
5 years to 17 years
People
60 worldwide
Run by
Amgen
See details and how to joinNCT04804553 · EU 2023-503435-17-00
Phase 3Taking people
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Where
Ancona, Florence, Milan, Padova, Pisa, Rome, Rozzano
Age
18 years and over
People
1,088 worldwide
Run by
Takeda
See details and how to joinNCT06671483 · EU 2024-513111-27-00
Phase 2Not yet taking people in Italy
An Exploratory Phase II, Randomized, Open-Label, Proof-of-Concept Trial Evaluating Add-on Polyunsaturated Fatty Acid Ethyl Esters on Pain and Minimal Disease Activity in Psoriatic Arthritis Patients Starting TNF-alpha Inhibitors
Where
Rome, Udine
Age
18 years and over
People
50
Run by
Fondazione Policlinico Universitario Campus Bio-medico In Forma A Bbreviata Fon
See details and how to join2026-526768-20-00 · EU 2026-526768-20-00
Phase 3Taking people
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Where
Florence, Naples
Age
5 years to 17 years
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06869551 · EU 2024-517262-41-00
Phase 3Taking people
An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptoms
Where
Rome
Age
18 years and over
People
370 worldwide
Run by
Universitaetsklinikum Erlangen AöR
See details and how to join2023-508251-39-00 · EU 2023-508251-39-00
Phase 4Taking people
IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY.
Where
Ferrara, Monza, Udine
Age
18 years and over
People
30
Run by
University Hospital Of Ferrara
See details and how to join2025-521259-21-00 · EU 2025-521259-21-00
Phase 3Taking people
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Where
Ancona, Florence, Milan, Padova, Pisa, Rome, Rozzano
Age
18 years and over
People
1,182 worldwide
Run by
Takeda
See details and how to joinNCT07286058 · EU 2025-522586-30-00
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Where
Florence, Milan, Rome
Age
5 years to 17 years
People
40 worldwide
Run by
AbbVie
See details and how to joinNCT06100744 · EU 2023-506026-36-00
No phaseTaking people
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Where
Ancona, Brescia, Campobasso, Catania, Chieti, Milan, Naples, Pisa, Rome, Rozzano, Siena, Udine
Age
18 years to 75 years
People
1,200 worldwide
Run by
AbbVie
See details and how to joinNCT06764693
Phase 4Not yet taking people in Italy
Arthritis interception with Guselkumab in subclinical psoriatic arthritis patients in clinical transition from skin to joint disease: a randomized clinical trial.
Where
Ancona, Brunico, Ferrara, Udine
Age
18 years and over
People
90
Run by
Azienda Sanitaria Universitaria Friuli Centrale
See details and how to join2025-523551-54-00 · EU 2025-523551-54-00
Phase 3Not yet taking people in Italy
Clinical and ultrasound assessment of the therapeutic response to ixekizumab in psoriatic arthritis dactlylitis; a multicentre, parallel-groups, randomised controlled trial
Where
Ancona, Milan, Padova, Palermo, Pavia, Perugia, Roma, Rome, Turin
Age
18 years and over
People
60
Run by
Azienda Ospedaliera Ordine Mauriziano Di Torino
See details and how to join2022-503119-40-00 · EU 2022-503119-40-00